merck p53 stapled peptide stapled peptides with in vivo activity - merrick-peptides prevents MDM2 from suppressing wild-type p53 Merck p53 Stapled Peptide: A Novel Approach in Cancer Therapy

merrifield-peptide-synthesis-pdf The merck p53 stapled peptide represents a significant advancement in the field of oncology, offering a novel therapeutic strategy by targeting the crucial p53 protein. This innovative approach leverages the power of stapled peptides to enhance the stability and efficacy of peptides designed to interact with and modulate the function of p53, a key tumor suppressorStapled α−helical peptide drug development: A potent dual .... Research into stapled peptides has paved the way for the development of molecules that can overcome the limitations of traditional peptides, such as poor bioavailability and rapid degradation64 Cu-Labeled Stapled Peptide-Based Radiopharmaceuticals ....

At the core of this therapeutic strategy is the P53 protein's role in cellular regulation. Wild-type p53 acts as a crucial guardian of the genome, detecting DNA damage and initiating cellular responses that can include cell cycle arrest, DNA repair, or programmed cell death (apoptosis).Stapled Peptide-based radiotheranostics agent targeting ... However, in many cancers, the p53 pathway is compromised, either through mutation or inactivation by other proteins.2025年10月25日—Finally, targeted radionuclide therapy confirmed that [64Cu]Cu-DOTA-STP effectively inhibited tumor growth, irrespective ofp53phenotypes. One of the primary mechanisms for p53 inactivation involves its binding to negative regulators like MDM2 and MDMX. These interactions lead to the ubiqui­tinylation and subsequent degradation of p53, thereby promoting tumor growth and survival.2025年10月25日—Finally, targeted radionuclide therapy confirmed that [64Cu]Cu-DOTA-STP effectively inhibited tumor growth, irrespective ofp53phenotypes.

Stapled peptides offer a unique solution to this problem. Unlike linear peptides, stapled peptides are engineered with a chemical "staple" that locks them into a specific three-dimensional conformation, mimicking the alpha-helical structure crucial for binding to target proteins.Optimal Stapling of a Helical Peptide‐Foldamer Hybrid Using ... This stabilization significantly improves their resistance to enzymatic degradation and enhances their cell permeability. For instance, the development of stapled peptides like ALRN-6924 has demonstrated the potential of these molecules as cell-penetrating stapled alpha-helical peptides designed to potently disrupt the interaction between p53 and its negative regulators, MDM2 and MDMX.Probing p53 Activating Stapled-Peptide Interaction with ... This disruption can effectively restore p53 activity, leading to cancer cell death.2025年2月27日—We next investigated the activity of thestapled diurea-peptide 8 ain cells and its ability to restore the p53 signalling pathway.

The merck p53 stapled peptide research aligns with this broader effort to reactivate the p53 pathway. Studies have explored various stapled peptide designs, including those with bicyclic stapled peptide p53-16, which has shown improved alpha-helicity and proteolytic stability, alongside nanomolar binding affinity2025年10月25日—Finally, targeted radionuclide therapy confirmed that [64Cu]Cu-DOTA-STP effectively inhibited tumor growth, irrespective ofp53phenotypes.. The ability of these stapled peptides to bind effectively to targets like MDM2 is critical.2023年7月27日—This drug candidate ismeant to mimic a key helix in the p53 protein, famous as a regulatory system in oncology, and to thus bind to its MDM2 ... For example, the stapled p53 peptide structure bound to Mdm2 has been elucidated, providing valuable insights into the molecular basis of their inhibitory action.

Furthermore, the therapeutic potential of stapled peptides extends beyond direct inhibition作者：M Payton·2017·被引用次数：9—ALRN-6924 is a cell-penetrating stapled alpha-helical peptidedesigned to equipotently disrupt the interaction between the p53 tumor suppressor protein and .... Research into stapled peptide drug development has focused on creating potent dual inhibitors of MDM2 and MDMX, such as ATSP-7041, which effectively activate the p53 pathway in tumors. This dual inhibition strategy is particularly promising for p53-dependent cancer therapy. The development of stapled peptides with in vivo activity is a key focus, ensuring that these molecules can exert their therapeutic effects systemically.作者：YS Chang·2013·被引用次数：812—We report a potent and selective dual inhibitor of MDM2 and MDMX, ATSP-7041, which effectively activates thep53pathway in tumors in vitro and in vivo.

The pursuit of effective stapled peptide therapeutics also involves optimizing their properties for clinical use. This includes investigating novel stapling chemistries and designing stapled peptides that can target specific cancer types or even facilitate targeted delivery作者：YH Lau·2014·被引用次数：76—Stapling peptides for inhibiting the p53/MDM2 interactionis a promising strategy for developing anti-cancer therapeutic leads. We evaluate double-click .... For example, stapled peptide-based radiotheranostic agents are being developed for PET-imaging guided radiotherapy of p53 mutant cancer, showcasing the versatility of this technology. The concept of stapled peptides shapeshifting to slip through cellular barriers highlights ongoing research into improving their pharmacokinetic profiles2025年2月27日—We next investigated the activity of thestapled diurea-peptide 8 ain cells and its ability to restore the p53 signalling pathway..

In summary, the merck p53 stapled peptide initiative is part of a larger scientific endeavor to harness the power of stapled peptides for cancer treatment. By stabilizing peptides and enhancing their ability to interact with critical proteins like p53 and its regulators MDM2 and MDMX, these engineered molecules offer a promising avenue for preventing MDM2 from suppressing wild-type p53 and reinstating its tumor-suppressive functions. The ongoing research into stapled peptides, including their design, synthesis, and clinical application, underscores their potential to become a cornerstone of future cancer therapies, offering hope for patients with various types of malignancies2025年8月8日—The novel stapled peptide PM2prevents MDM2 from suppressing wild-type p53, and is thus a promising agent for therapeutic combination with EBRT..